KLK3 and posterior cortical atrophy: Currently available tools for risk stratification of PCa patients, which include diagnostic serum PSA levels, clinical stage (cTNM) and Gleason score in biopsy 5, 6, are helpful but limited in their ability to accurately predict outcome or tumor aggressiveness 5, 7.